Heidelberg Pharma to Showcase HDP-101 Efficacy and ADC Technology at AACR 2024

Heidelberg Pharma AG announces its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, from April 5-10, 2024. The company intends to present first efficacy data from its Phase I clinical trial of HDP-101 and preclinical data from other candidates within its proprietary Antibody Drug Conjugates (ADCs) platform.

Among the presentations, details on a late-breaking research poster featuring a novel therapeutic modality for colorectal cancer treatment and a clinical trials poster demonstrating promising initial results of HDP-101 in relapsed multiple myeloma patients will be highlighted. Another significant presentation will discuss preclinical data of HDP-102, indicating its potential as a new treatment for Non-Hodgkin’s lymphoma (NHL).

Additionally, a study elucidating the off-target toxicity mechanisms of ATACs will be presented, showing how altering specific amino acids in the antibody reduces liver toxicity, suggesting an improvement in the therapeutic window of these ADCs.

This series of presentations mark a significant milestone for Heidelberg Pharma, highlighting its dedication to advancing ADC technology and providing new treatment options for cancer patients.